XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
Note 6 - Licenses, Royalty Collaborative and Contractual Arrangements (Details Textual) (USD $)
In Millions, unless otherwise specified
 9 Months Ended 1 Months Ended
Mar. 31, 2015
Mar. 31, 2011
GSK [Member] | United States, Europe, Japan, And Other Countries [Member]    
Royalty Payment Percentage 7.00%bota_RoyaltyPaymentPercentage
/ us-gaap_CounterpartyNameAxis
= bota_GSKMember
/ us-gaap_StatementGeographicalAxis
= bota_UnitedStatesEuropeJapanAndOtherCountriesMember		  
GSK [Member] | Australia, New Zealand, South Africa, and Indonesia [Member]    
Royalty Payment Percentage 10.00%bota_RoyaltyPaymentPercentage
/ us-gaap_CounterpartyNameAxis
= bota_GSKMember
/ us-gaap_StatementGeographicalAxis
= bota_AustraliaNewZealandSouthAfricaAndIndonesiaMember		  
Daiichi Sankyo [Member] | Japan [Member]    
Royalty Payment Percentage 4.00%bota_RoyaltyPaymentPercentage
/ us-gaap_CounterpartyNameAxis
= bota_DaiichiSankyoMember
/ us-gaap_StatementGeographicalAxis
= bota_JapanMember		  
BARDA [Member]    
Maximum Revenue From Contract   $ 231.2bota_MaximumRevenueFromContract
/ us-gaap_CounterpartyNameAxis
= bota_BARDAMember
Contract Term   5 years